GCH1 Knockout HACAT Cell Line

The choice depends on whether you are studying GCH1 (GTP cyclohydrolase 1)'s role as the rate-limiting enzyme of tetrahydrobiopterin (BH4) biosynthesis or modeling dopa-responsive dystonia (Segawa syndrome) and chronic pain GWAS associations. The Knockout line is the standard tool for asking whether GCH1 is required for these processes — GCH1 catalyzes the first and rate-limiting step of de novo BH4 biosynthesis (GTP → 7,8-dihydroneopterin triphosphate), generating BH4 as an essential cofactor for aromatic amino acid hydroxylases (PAH, TH, TPH), nitric oxide synthases (NOS), and alkylglycerol monooxygenase. Overexpression is useful for studying GCH1 gain-of-function effects. For BH4 biology research, the EDITGENE GCH1 Knockout in HaCaT is informative — HaCaT is a human keratinocyte cell line, providing a skin/peripheral context for BH4 metabolism research. GCH1 dominant-negative mutations cause dopa-responsive dystonia (Segawa syndrome, autosomal dominant DOPA-responsive dystonia); GCH1 polymorphisms are associated with chronic pain susceptibility (one of the strongest pain GWAS loci). Rescue with wild-type or catalytically-dead GCH1 enables structure-function studies. The knockout is valuable for studying BH4-dependent enzymes (NOS, aromatic amino acid hydroxylases), dopa-responsive dystonia, and emerging BH4-related therapeutics (sapropterin/Kuvan for PKU).

Primary applications: • BH4 quantification: cellular BH4 and BH2 levels by HPLC or LC-MS in GCH1-null versus rescued cells. • NOS coupling: NO versus superoxide production (DAF-FM versus DHE) given BH4's role in NOS coupling versus uncoupling. • Dopa-responsive dystonia modeling: rescue with patient-derived GCH1 dominant-negative mutations for genotype-function studies of Segawa syndrome. • Chronic pain GWAS studies: rescue with pain-associated GCH1 polymorphisms for pharmacogenomic studies. EDITGENE recommends this HaCaT-based model for researchers investigating BH4 biology, NOS function, dopa-responsive dystonia mechanisms, and emerging BH4-related therapeutics.

Yes. GCH1 rescue experiments are well-established for BH4 biology research: • Construct design: use a codon-modified GCH1 sequence with a small C-terminal tag (FLAG, HA). GCH1 functions as a homodecamer (two homopentamers) — preserve oligomerization-relevant regions. • Catalytically-dead rescue: active site residue mutations abolish GTP cyclohydrolase activity and serve as the standard specificity control. • Dopa-responsive dystonia mutation rescue: patient-derived dominant-negative GCH1 mutations enable disease genotype-function studies. • Pain GWAS variant rescue: pain-associated GCH1 polymorphisms enable pharmacogenomic studies. • Functional readout: rescue should restore cellular BH4 levels measured by HPLC and downstream NOS/aromatic amino acid hydroxylase function. HaCaT-specific considerations: • HaCaT is a spontaneously immortalized human keratinocyte cell line widely used for skin biology, wound healing, and keratinocyte differentiation research. • Lentiviral transduction efficiency is moderate; standard keratinocyte culture conditions are required. • HaCaT retains many keratinocyte features but may differ from primary keratinocytes in some respects — confirm relevant phenotypes in primary models when possible.